Stay updated on Nivolumab and Urelumab in Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Urelumab in Bladder Cancer Clinical Trial page.
Latest updates to the Nivolumab and Urelumab in Bladder Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe study locations were updated to include California, Colorado, Illinois, Maryland, and New York; the page revision was updated to v3.3.3; and the HHS Vulnerability Disclosure link was removed.SummaryDifference0.7%
- Check18 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedRevision: v3.3.2 added, replacing Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check47 days agoChange DetectedRemoved the government funding status notice from the page, which previously warned that information might not be up to date and that NIH operations could be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check61 days agoChange DetectedNo additions or deletions were detected on the page; the content appears unchanged.SummaryDifference0.5%
- Check90 days agoChange DetectedUpdate includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. The core effect is informing users about possible delays and the current open status of the NIH Clinical Center.SummaryDifference3%
- Check97 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. This is a metadata revision with no substantive content changes.SummaryDifference0.1%
Stay in the know with updates to Nivolumab and Urelumab in Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Urelumab in Bladder Cancer Clinical Trial page.